A patient in their late 40s arrives asking about “peptides for energy and recovery” after reading that they boost growth hormone without the risks of injecting growth hormone itself. As more nurse practitioners build out anti-aging, hormone-optimization, and recovery-focused practices, that conversation is becoming routine — and sermorelin, ipamorelin, and CJC-1295 are the three names that come up most. All three are growth-hormone secretagogues: rather than replacing growth hormone, they prompt the patient’s own pituitary to release it. But they are not interchangeable. They differ in mechanism, half-life, dosing rhythm, side-effect profile, and — critically for prescribers — regulatory status. This guide compares the three head-to-head so NPs can understand who uses which agent, why, and what competency the prescribing decision actually requires. 

How Growth-Hormone Secretagogues Work 

To compare these three peptides, you first have to separate them into two pharmacologic families, because that distinction drives almost everything else. 

The hypothalamic–pituitary axis controls endogenous growth hormone (GH) release through two opposing signals: growth-hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which suppresses it. GH then acts largely through insulin-like growth factor 1 (IGF-1), produced mainly in the liver, which is the analyte clinicians track. Secretagogues work upstream of GH itself, on this regulatory machinery. 

• GHRH analogs mimic the body’s own releasing hormone and bind the GHRH receptor on the pituitary. Sermorelin and CJC-1295 belong to this class. Because they amplify the existing pulsatile signal rather than overriding it, GHRH analogs are generally described as preserving the physiologic feedback loop — the pituitary can still be restrained by somatostatin, which theoretically limits supraphysiologic spikes. 

• Growth-hormone-releasing peptides (GHRPs) / ghrelin-receptor agonists act through a different receptor — the GH secretagogue receptor (the ghrelin receptor) — and also suppress somatostatin. Ipamorelin belongs to this class. GHRPs are frequently combined with a GHRH analog because the two mechanisms are synergistic: stimulating release through one pathway (the GHRH receptor) while disinhibiting it through the other (suppressing somatostatin via the ghrelin receptor). 

That two-family split — GHRH analog vs. GHRP — is the single most useful mental model for these agents. It explains why ipamorelin is so often paired with CJC-1295, and why sermorelin is usually used on its own. 

A useful way to frame the goal of this drug class for patients is pituitary reserve — the preservation of the pituitary’s own hormone-producing capacity. Rather than supplying GH from outside, secretagogues work the gland’s native machinery, which is positioned as a way to help maintain that reserve and offset the age-related decline in pituitary GH output. This concept is covered in depth in the Anti-Aging & Peptide Course. 

Sermorelin, Ipamorelin & CJC-1295: A Head-to-Head Comparison 

The table below summarizes the practical differences a prescriber weighs. The dosing rhythm shown reflects each agent’s pharmacology (how its half-life shapes administration), not a prescribing protocol — specific doses, titration, and combination regimens are clinical decisions covered in the Anti-Aging & Peptide Course and should be set against a current primary source and the compounding pharmacy’s product information. 

A few clarifications the table can’t fully carry: 

• “CJC-1295” is ambiguous — but only one form reaches patients. The name refers to two different molecules: CJC-1295 without DAC (also called Mod-GRF or mod GRF 1-29), which is short-acting (~30 min),[^pk-cjc-nodac] and CJC-1295 with DAC (drug affinity complex), which binds albumin and extends the half-life to roughly 6–8 days (about a week).[^pk-cjc-dac] In practice this distinction is settled for prescribers: compounding pharmacies dispense only the no-DAC (Mod-GRF) version. The DAC version exists pharmacologically but is not offered through legitimate compounding channels, so any clinical conversation about “CJC-1295” should be understood to mean the no-DAC/Mod-GRF form. Documenting which form is meant remains a prescribing-safety habit. 

• Sermorelin is the most “established” of the three. It was previously an FDA-approved product — marketed as Geref (sermorelin acetate) and approved for the diagnosis and treatment of growth-hormone deficiency, not anti-aging.[^geref-nda] The manufacturer (EMD Serono) discontinued Geref in 2008 for commercial reasons, and the FDA later confirmed it was not withdrawn for reasons of safety or effectiveness.[^geref-withdrawal] That history is why sermorelin is often presented as the better-characterized option, even though no branded product is currently marketed for optimization use. 

Indications and Patient Selection 

Sermorelin was originally FDA-approved for growth-hormone deficiency, not anti-aging, and all three of these agents are off-label for anti-aging and GH optimization — used symptomatically, with no strong anti-aging evidence behind them. Any use in that context is by definition outside an approved indication, and that candor belongs in the informed-consent conversation. With that framing fixed, the clinical scenarios where these agents are discussed include: 

• Symptomatic adult relative GH decline (“somatopause”). GH and IGF-1 fall with age, and a subset of patients present with fatigue, poor recovery, reduced lean mass, and sleep complaints. Secretagogues are positioned as a way to nudge endogenous GH upward without exogenous GH — and to help preserve pituitary reserve. The evidence for symptomatic benefit in otherwise-healthy aging adults is limited; there is no strong anti-aging outcome data, and that should be presented candidly to patients. 

• Recovery, body composition, and sleep goals, typically in a cash-pay optimization setting. Patient expectations frequently outrun the evidence here, which is precisely where prescriber judgment and informed consent matter. 

• Adjacent hormone-optimization patients. Many GH-secretagogue candidates are already in an NP’s hormone practice for testosterone, perimenopause, or thyroid management — which is why this topic sits alongside broader hormone training (see the cross-link to HRT certification below). 

Patient selection is also about who not to treat — and it is worth distinguishing absolute from relative contraindications. Important cautions to screen for: 

• Active malignancy or history of cancer. Because the GH/IGF-1 axis is mitogenic, active or recent malignancy is generally treated as a contraindication to GH-axis stimulation. 

• Diabetes — a relative, not absolute, contraindication. GH is counter-regulatory to insulin, so uncontrolled diabetes is a reason to hold these agents. In well-controlled diabetic patients, however, GH secretagogues may actually improve glucose handling over time — via reduced visceral fat and increased lean body mass. The decision is therefore individualized around glycemic control, not a blanket exclusion; glucose status should be assessed and monitored throughout. 

• Proliferative diabetic retinopathy, active severe illness, and pregnancy/lactation are commonly cited cautions. 

• Untreated pituitary or hypothalamic pathology — a GHRH analog needs a functioning pituitary to work, and unexplained IGF-1 derangements warrant endocrine workup before empiric peptide use. 

Monitoring: IGF-1 and Safety Labs 

Because GH is released in pulses and cleared quickly, a random GH level is not a useful monitoring tool. IGF-1 is the standard surrogate for integrated GH activity and is the analyte to trend. A defensible monitoring posture described in the optimization literature looks like this — confirm specifics against current guidance: 

• Baseline: IGF-1 (age- and sex-adjusted reference range), fasting glucose and/or HbA1c, and a broader metabolic panel; consider baseline assessment for any patient where GH-axis pathology is plausible. 

• Follow-up: Re-check IGF-1 during the titration phase and periodically thereafter, targeting the age-adjusted reference range rather than supraphysiologic levels. The Endocrine Society’s adult GH-deficiency guideline frames the analogous monitoring for GH replacement as clinical and IGF-1 review at 1–2 month intervals during dose titration and semiannually thereafter, with IGF-1 kept within the age-adjusted reference range (a commonly used target being the upper half of that range).[^es-monitoring] Specific intervals and targets for secretagogue therapy are individualized; detailed monitoring is covered in the Anti-Aging & Peptide Course. 

• Ongoing safety: periodic glucose/HbA1c given GH’s effect on glucose handling; clinical reassessment of edema, arthralgia, and carpal-tunnel-type symptoms, which are the classic dose-related GH-excess effects. 

Red flags that should prompt dose reduction or workup include IGF-1 climbing above the age-adjusted range, new or worsening glucose dysregulation, and fluid-retention symptoms. Documentation tying IGF-1 results, symptoms, and dosing decisions together is both good care and the prescriber’s liability protection — the same principle that applies across hormone-optimization practice. 

Safety, Side Effects & Contraindications 

The side-effect profile of GH secretagogues is generally described as mild and largely mechanism-based — i.e., the predictable consequences of raising GH/IGF-1, plus injection-site and pathway-specific effects: 

• Injection-site reactions (these are subcutaneous injections): redness, itching, transient swelling. 

• GH-excess–type effects when dosing pushes IGF-1 high: fluid retention/edema, arthralgias, paresthesias/carpal-tunnel symptoms, headache. 

• Glucose effects: GH is counter-regulatory to insulin, which matters most in uncontrolled diabetes; in well-controlled patients the net metabolic effect over time can be favorable (see patient selection above). 

• GHRP-specific: unlike older GHRPs such as hexarelin and GHRP-6, which can stimulate appetite, ipamorelin has negligible appetite stimulation — it is highly GH-selective, with little effect on cortisol or prolactin. This selectivity is a large part of why ipamorelin is the preferred GHRP in optimization practice. 

• Theoretical mitogenic risk from sustained IGF-1 elevation — the rationale behind the malignancy contraindication and against chasing supraphysiologic levels. 

The honest summary for patients: short-term tolerability in the literature is generally favorable, but long-term safety and hard outcome data in healthy aging adults are limited, and these agents are being used outside an FDA-approved indication. 

Regulatory Status: FDA Approval & Compounding 

This is the part of the conversation NPs cannot afford to get wrong, and it is changing. 

• None of these three peptides is currently marketed as an FDA-approved drug for GH optimization or anti-aging. When patients receive them, they are almost always compounded by a pharmacy. 

• The compounding landscape tightened — and is now actively shifting. The FDA has scrutinized many peptides used in compounding. Both ipamorelin and CJC-1295 were nominated to “Category 2” of the agency’s interim 503A bulk-substance review (substances flagged with significant safety concerns or insufficient data); the nominations were then withdrawn by the nominators in September 2024, and the FDA removed both substances from the Category 2 interim list.[^cat2-removal] The agency reviewed them on its own initiative at the Pharmacy Compounding Advisory Committee (PCAC), which voted against adding either to the 503A bulks list (ipamorelin on Oct 29, 2024; CJC-1295 on Dec 4, 2024).[^pcac-vote] In February 2026, HHS announced an intent to move most of the affected peptides — including ipamorelin and CJC-1295 — back toward Category 1, with a further PCAC review scheduled for July 2026.[^cat2-2026] The practical effect for prescribers is the same caution either way: the regulatory standing of these peptides is unsettled and moving. Because this picture is fast-moving, the dates above are stated as of mid-2026 — always defer to the FDA’s own current list of certain bulk drug substances that may present significant safety risks and the latest PCAC outcome before relying on any classification here. Elite NP tracks these developments in its FDA-peptide resource; link to the current FDA-status article at publish for the live picture. 

• Sourcing — use only FDA-registered compounding pharmacies. Legitimate use runs through an FDA-registered 503A or 503B compounding pharmacy operating within current FDA constraints. Never use research-use-only (RUO / “for research use only”), “research” peptides, or black-market sources — these are not lawfully prescribable, are not made to pharmaceutical-grade standards, and carry clear regulatory and patient-safety exposure. 

• Controlled-substance status. These secretagogues are not federally scheduled controlled substances in the way testosterone is. However, performance-enhancement and anti-doping rules are a separate matter — GH secretagogues and GHRH analogs are prohibited in sport under the WADA Prohibited List. The current (2026) list classes them under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which is prohibited at all times (both in- and out-of-competition); subsection S2.2.4 names GHRH and its analogues (including sermorelin and CJC-1295) and growth-hormone secretagogues (including ipamorelin) explicitly.[^wada] 

[!warning] Verify before you prescribe FDA peptide-compounding policy and 503A bulk-substance status are actively evolving. Confirm the current regulatory standing of any peptide, and your state-specific prescribing and compounding rules, against primary sources before clinical use. Source only from FDA-registered 503A/503B compounding pharmacies — never research-use-only or black-market peptides. No approval numbers are stated here by design. (YMYL regulatory facts in this article should also be run through the nursing-requirements-verifier before publish.) 

Why Competency Training Matters for NPs 

Deciding which GH secretagogue to use — and whether to use one at all — is not a memorize-a-protocol task. It requires the prescriber to integrate pharmacology (GHRH vs. GHRP, DAC vs. no-DAC), IGF-1-based monitoring, glucose and malignancy screening, a fast-moving compounding-regulatory picture, and a candid informed-consent conversation about an off-label therapy with limited long-term data. That is a lot of moving parts to assemble safely from blog posts and pharmacy handouts. 

Structured, NP-focused training is what turns this from a risky add-on into a defensible clinical service. If you’re new to this drug class generally, start with the foundational primer, What Is Peptide Therapy? A Clinical Primer for NPs, which situates secretagogues within the broader peptide landscape. Because most GH-secretagogue candidates overlap with hormone-optimization patients, the Elite NP HRT Certification is a natural companion for the wider endocrine context. And for the peptide-specific prescribing competency — patient selection, monitoring, sourcing, and the regulatory guardrails — the Anti-Aging & Peptide Course is the dedicated training built for nurse practitioners. 

Frequently Asked Questions 

What is the difference between sermorelin and ipamorelin? 

Sermorelin is a GHRH analog that binds the GHRH receptor to stimulate growth-hormone release, while ipamorelin is a growth-hormone-releasing peptide (GHRP) that works through the separate ghrelin (GH secretagogue) receptor. Because they act on different receptors, they are often co-compounded rather than chosen one-or-the-other. Ipamorelin is also highly GH-selective — with little effect on cortisol or prolactin and negligible appetite stimulation, unlike older GHRPs such as hexarelin or GHRP-6. 

Is sermorelin FDA-approved? 

No sermorelin product is currently marketed in the US as an FDA-approved drug for growth-hormone optimization or anti-aging; it is typically compounded. A sermorelin product was previously FDA-approved for the diagnosis and treatment of growth-hormone deficiency — not anti-aging — before being withdrawn from the market for commercial reasons. Like ipamorelin and CJC-1295, sermorelin is used off-label for anti-aging, and patients should source it only through an FDA-registered 503A or 503B compounding pharmacy. 

Why is ipamorelin combined with CJC-1295? 

The two are commonly co-compounded because they raise growth hormone through complementary mechanisms — CJC-1295 (a GHRH analog) stimulates the GHRH receptor while ipamorelin (a GHRP) activates the ghrelin receptor and suppresses somatostatin — giving a synergistic effect from pairing a GHRH analog with a GHRP. Note that compounding pharmacies dispense only the short-acting no-DAC (Mod-GRF) form of CJC-1295, which is the form used in these pairings. 

How is growth-hormone secretagogue therapy monitored? 

IGF-1 is the standard monitoring lab, because growth hormone itself is released in pulses and cleared too quickly for a single level to be meaningful. Clinicians typically check a baseline IGF-1, recheck after initiation, and aim for the upper end of the age-adjusted normal range rather than supraphysiologic levels — alongside periodic glucose monitoring given growth hormone’s effect on glucose handling. 

Can nurse practitioners prescribe sermorelin, ipamorelin, or CJC-1295? 

In general, NPs with prescriptive authority can prescribe compounded peptides where state scope of practice allows, since these secretagogues are not federally scheduled controlled substances. The harder questions are regulatory and clinical: the FDA’s evolving peptide-compounding rules, lawful sourcing through an FDA-registered compounding pharmacy (never research-use-only or black-market peptides), and the competency to select patients and monitor safely. Always verify current FDA status and your state rules before prescribing. 

Conclusion 

Sermorelin, ipamorelin, and CJC-1295 all raise endogenous growth hormone, but they are distinct tools: sermorelin and CJC-1295 are GHRH analogs, ipamorelin is a GHRP, and “CJC-1295” itself hides a critical short-acting-vs-long-acting (DAC) distinction. For NPs, the real skill is matching agent to patient, monitoring with IGF-1, and staying current on a compounding-regulatory picture that is actively shifting. If GH secretagogues are part of the practice you’re building, train for them deliberately. Build the prescribing competency with the Elite NP Anti-Aging & Peptide Course — a clinical curriculum designed for nurse practitioners. 

Sources 

Regulatory and pharmacokinetic facts verified against primary sources; access date 2026-06-26. 

Sermorelin is a synthetic analog of the first 29 amino acids of GHRH and is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV), giving it a short half-life. In a controlled-infusion study in healthy men, native GHRH-(1-29)-NH₂ showed an intravenous disappearance half-life of 4.3 ± 1.4 minutes; the ~10–20 minute figure commonly cited for subcutaneous clinical use reflects this rapid enzymatic clearance. Frohman LA, et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. PubMed 7962295. See also Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308. PMC2699646 (clinical review of sermorelin). Access date 2026-06-26. 

Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412–1416. Reported a short terminal half-life of ~2 hours in healthy volunteers. https://doi.org/10.1023/A:1018955126402 — Access date 2026-06-26. 

CJC-1295 without DAC (modified GRF 1-29 / “Mod-GRF”) lacks the albumin-binding drug-affinity-complex linker and has a short plasma half-life of approximately 30 minutes, consistent with the unmodified GHRH(1-29) backbone. https://en.wikipedia.org/wiki/CJC-1295 — Access date 2026-06-26. 

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. The DAC form binds circulating albumin (cysteine-34) and showed an estimated terminal half-life of 5.8–8.1 days (≈6–8 days), with IGF-1 elevations sustained ~9–11 days after a single dose. https://doi.org/10.1210/jc.2005-1536 — Access date 2026-06-26. 

Geref (sermorelin acetate) was an FDA-approved product: NDA 019863 (0.05 mg base/amp, approved Dec 28, 1990, diagnostic use) and NDA 020443 (0.5 and 1.0 mg base/vial, approved Sept 26, 1997, for idiopathic GH deficiency in children), held by EMD Serono — approved for diagnosis/treatment of growth-hormone deficiency, not anti-aging. U.S. Food and Drug Administration, Federal Register notice 78 FR 14159 (Mar 4, 2013), “Determination That GEREF (Sermorelin Acetate) Injection … Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.” https://www.federalregister.gov/documents/2013/03/04/2013-04827/ — Access date 2026-06-26. 

In December 2008, EMD Serono notified FDA that Geref was being discontinued and requested withdrawal of NDA 020443; the discontinuation was a commercial decision. FDA subsequently determined the product was not withdrawn from sale for reasons of safety or effectiveness (Federal Register, 78 FR 14159, Mar 4, 2013). https://www.federalregister.gov/documents/2013/03/04/2013-04827/ — Access date 2026-06-26. 

The nominations for CJC-1295 and ipamorelin acetate (among other peptides) to the FDA interim Category 2 bulk-substances list were withdrawn by the nominators, and FDA removed them from that list effective Sept 27, 2024 (announced Sept 20, 2024). FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks — Access date 2026-06-26. 

After the nominations were withdrawn, FDA referred the substances to its Pharmacy Compounding Advisory Committee (PCAC) on its own initiative. PCAC reviewed ipamorelin on Oct 29, 2024 and CJC-1295 (including DAC forms) on Dec 4, 2024, voting against recommending either for inclusion on the 503A bulks list. FDA PCAC meeting materials, Oct 29 & Dec 4, 2024. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee — Access date 2026-06-26. 

On Feb 27, 2026, HHS announced an intent to move approximately 14 of the ~19 peptides then on the Category 2 list — including ipamorelin and CJC-1295 — back toward Category 1, with a further PCAC review scheduled for July 2026. This status is unsettled; re-confirm against the live FDA list before publication. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks — Access date 2026-06-26. 

Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609. Recommendation 5.3 advises monitoring at 1–2 month intervals during dose titration and semiannually thereafter (clinical assessment, adverse-effect evaluation, and IGF-I), with IGF-I targeted within the age-adjusted reference range; Section 5.2 notes a commonly used target of the upper half of that range. This guideline addresses GH replacement in diagnosed adult GH deficiency; it is cited here as the analogous monitoring framework for IGF-1-guided therapy, not as an endorsement of secretagogue use for optimization. https://doi.org/10.1210/jc.2011-0179 — Access date 2026-06-26. 

World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective Jan 1, 2026). Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) is prohibited at all times (in- and out-of-competition). Subsection S2.2.4 (Growth Hormone Releasing Factors) names GHRH and its analogues — explicitly including sermorelin and CJC-1295 (and CJC-1293, tesamorelin) — and growth-hormone secretagogues/mimetics including ipamorelin (and anamorelin, capromorelin, ibutamoren/MK-677, macimorelin, tabimorelin). https://www.wada-ama.org/en/prohibited-list — Access date 2026-06-26.